Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
Moderna said the FDA granted approval for its mRNA flu vaccine mFLUVISA. The FDA issued traditional approval for ages 50 to 64 and accelerated approval for ages 65 and older. Moderna expects availability in coming weeks, with no pricing disclosed. The company previously faced a refusal-to-file and an advisory committee vote supported approval. Jefferies expects sales to skew toward 2027.
How this was made
The 30-second read
Why it matters
The FDA’s approval ends the regulatory dispute and establishes a clear path to commercialization, with label differentiation by age group and a stated launch window in coming weeks.
Market read
This is a direct regulatory catalyst for Moderna tied to a new commercial product, with timing that can influence near-term positioning and longer-dated revenue expectations.
What to watch
Competitive dynamics in seasonal flu, manufacturing scale-up for a first-in-class mRNA flu shot, and the post-marketing trial outcomes for the 65+ accelerated segment could affect durability of the revenue ramp.
Background
mFLUVISA previously faced an FDA refusal-to-file in February over trial control-group adequacy, later accepted after revisions and an advisory committee vote.
Ticker impact
Moderna received FDA approval for mRNA flu vaccine mFLUVISA, including traditional approval for ages 50-64 and accelerated approval for 65+.
Near-term upside bias as traders price in reduced regulatory risk and incremental revenue optionality; follow-through depends on launch execution and uptake.
The article is a first-report regulatory greenlight with defined label expansion and explicit timing for availability, which typically drives repricing versus pre-approval uncertainty.
Market effects
Supports the broader mRNA vaccine platform narrative and may improve sentiment toward next-gen flu vaccine entrants.
Primarily US-focused due to FDA approval and US seasonal timing.
Could strengthen global expectations for mRNA flu commercialization, though the article is US-label specific.
Counterpoint
Even with approval, pricing and reimbursement are unknown, and sales may be back-end loaded into 2027, limiting near-term earnings impact.
Key entities
- companyModerna
Developer of mRNA-based flu vaccine mFLUVISA, now granted FDA approval with traditional and accelerated pathways by age.
- regulatorFDA
Granted approval for mFLUVISA after earlier refusal-to-file and subsequent revised application review.
- regulatory divisionCBER
FDA center overseeing biologics review; temporarily headed by Karim Mikhail per the article.
- regulatorVinay Prasad
Former CBER director who signed the February refusal-to-file letter criticizing the pivotal trial controls.
